MG
IMCR icon

Michael Gelband’s Immunocore IMCR Stock Holding History

Michael Gelband’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40,279
Closed -$1.21M – 1800
2026
Q1 		$1.21M Buy
+40,279
New +$1.3M 0.01% 941
2023
Q4 		– Sell
-72,159
Closed -$3.75M – 1736
2023
Q3 		$3.75M Buy
+72,159
New +$4.27M 0.04% 452

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Michael Gelband's IMCR Position: Q2 2026 in Review

Michael Gelband sold out of Immunocore (IMCR) in Q2 2026, closing a stake of 40,279 shares — an estimated $1.21M sold.

Michael Gelband first reported a position in IMCR in Q3 2023 and held it in 2 quarters. The position peaked at $3.75M in Q3 2023. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Michael Gelband reported no remaining Immunocore position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 40,279 Immunocore shares in Q2 2026, an estimated $1.21M.
  • Michael Gelband first reported a position in Immunocore in Q3 2023 and held it in 2 quarters.
  • Michael Gelband's Immunocore position peaked at $3.75M in Q3 2023.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.